Huaren Pharmaceutical Co., Ltd. (300110.SZ)
CNY 2.9
(3.2%)
CNY 2.9
(3.2%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.63 Billion CNY | 1.04% |
| 2022 | 1.61 Billion CNY | 3.76% |
| 2021 | 1.56 Billion CNY | 18.55% |
| 2020 | 1.31 Billion CNY | -9.94% |
| 2019 | 1.46 Billion CNY | 5.64% |
| 2018 | 1.38 Billion CNY | 5.49% |
| 2017 | 1.31 Billion CNY | 5.04% |
| 2016 | 1.24 Billion CNY | 12.94% |
| 2015 | 1.1 Billion CNY | 20.63% |
| 2014 | 916.76 Million CNY | 5.72% |
| 2013 | 867.2 Million CNY | 54.3% |
| 2012 | 562.03 Million CNY | 38.67% |
| 2011 | 405.31 Million CNY | 19.81% |
| 2010 | 338.3 Million CNY | 17.24% |
| 2009 | 288.54 Million CNY | 39.01% |
| 2008 | 207.57 Million CNY | 28.81% |
| 2007 | 161.14 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 364.75 Million CNY | -8.92% |
| 2024 Q3 | 297.16 Million CNY | -17.16% |
| 2024 Q1 | 400.46 Million CNY | -4.73% |
| 2023 Q3 | 386.88 Million CNY | -9.14% |
| 2023 Q4 | 420.32 Million CNY | 8.65% |
| 2023 FY | 1.63 Billion CNY | 1.04% |
| 2023 Q1 | 403.24 Million CNY | -21.72% |
| 2023 Q2 | 425.8 Million CNY | 5.6% |
| 2022 FY | 1.61 Billion CNY | 3.76% |
| 2022 Q2 | 336.47 Million CNY | -12.71% |
| 2022 Q3 | 382.42 Million CNY | 13.66% |
| 2022 Q4 | 515.1 Million CNY | 34.69% |
| 2022 Q1 | 385.48 Million CNY | -10.04% |
| 2021 Q3 | 429.57 Million CNY | 19.51% |
| 2021 FY | 1.56 Billion CNY | 18.55% |
| 2021 Q1 | 343.34 Million CNY | 13.02% |
| 2021 Q2 | 359.43 Million CNY | 4.68% |
| 2021 Q4 | 428.5 Million CNY | -0.25% |
| 2020 FY | 1.31 Billion CNY | -9.94% |
| 2020 Q3 | 426.35 Million CNY | 23.23% |
| 2020 Q4 | 303.78 Million CNY | -28.75% |
| 2020 Q1 | 240.47 Million CNY | -35.12% |
| 2020 Q2 | 345.97 Million CNY | 43.87% |
| 2019 Q3 | 379.45 Million CNY | 0.12% |
| 2019 FY | 1.46 Billion CNY | 5.64% |
| 2019 Q1 | 332.83 Million CNY | -11.75% |
| 2019 Q2 | 379 Million CNY | 13.87% |
| 2019 Q4 | 370.64 Million CNY | -2.32% |
| 2018 Q1 | 323.05 Million CNY | -18.76% |
| 2018 FY | 1.38 Billion CNY | 5.49% |
| 2018 Q4 | 377.16 Million CNY | 5.91% |
| 2018 Q2 | 327.51 Million CNY | 1.38% |
| 2018 Q3 | 356.11 Million CNY | 8.73% |
| 2017 Q3 | 327.85 Million CNY | 3.95% |
| 2017 Q4 | 397.67 Million CNY | 21.29% |
| 2017 FY | 1.31 Billion CNY | 5.04% |
| 2017 Q2 | 315.39 Million CNY | 16.4% |
| 2017 Q1 | 270.95 Million CNY | -20.3% |
| 2016 Q4 | 339.95 Million CNY | 4.03% |
| 2016 Q1 | 276.13 Million CNY | -7.9% |
| 2016 Q2 | 306.1 Million CNY | 10.85% |
| 2016 Q3 | 326.77 Million CNY | 6.75% |
| 2016 FY | 1.24 Billion CNY | 12.94% |
| 2015 FY | 1.1 Billion CNY | 20.63% |
| 2015 Q2 | 258.9 Million CNY | 6.8% |
| 2015 Q3 | 304.75 Million CNY | 17.71% |
| 2015 Q4 | 299.81 Million CNY | -1.62% |
| 2015 Q1 | 242.42 Million CNY | 17.41% |
| 2014 Q3 | 301.94 Million CNY | 43.95% |
| 2014 Q4 | 206.47 Million CNY | -31.62% |
| 2014 Q1 | 198.58 Million CNY | -32.37% |
| 2014 Q2 | 209.75 Million CNY | 5.63% |
| 2014 FY | 916.76 Million CNY | 5.72% |
| 2013 Q3 | 209.65 Million CNY | 3.23% |
| 2013 Q1 | 160.8 Million CNY | -14.5% |
| 2013 Q4 | 293.64 Million CNY | 40.06% |
| 2013 FY | 867.2 Million CNY | 54.3% |
| 2013 Q2 | 203.09 Million CNY | 26.3% |
| 2012 Q2 | 130.24 Million CNY | 29.43% |
| 2012 Q4 | 188.07 Million CNY | 31.44% |
| 2012 Q1 | 100.63 Million CNY | -15.71% |
| 2012 FY | 562.03 Million CNY | 38.67% |
| 2012 Q3 | 143.08 Million CNY | 9.86% |
| 2011 FY | 405.31 Million CNY | 19.81% |
| 2011 Q3 | 105.83 Million CNY | 12.2% |
| 2011 Q2 | 94.32 Million CNY | 9.96% |
| 2011 Q4 | 119.38 Million CNY | 12.81% |
| 2011 Q1 | 85.77 Million CNY | -1.36% |
| 2010 FY | 338.3 Million CNY | 17.24% |
| 2010 Q1 | 77.53 Million CNY | 1.32% |
| 2010 Q2 | 93.89 Million CNY | 21.1% |
| 2010 Q3 | 79.91 Million CNY | -14.89% |
| 2010 Q4 | 86.96 Million CNY | 8.82% |
| 2009 Q3 | 81.52 Million CNY | 0.0% |
| 2009 Q4 | 76.52 Million CNY | -6.14% |
| 2009 FY | 288.54 Million CNY | 39.01% |
| 2008 FY | 207.57 Million CNY | 28.81% |
| 2007 FY | 161.14 Million CNY | 0.0% |